114 related articles for article (PubMed ID: 38327230)
1. Oridonin loaded peptide nanovesicles alleviate nonalcoholic fatty liver disease in mice.
Zhang L; Yu Y; Wang Q; Huang X; Feng Z; Li Z
Pharm Dev Technol; 2024 Feb; 29(2):123-130. PubMed ID: 38327230
[TBL] [Abstract][Full Text] [Related]
2. Oridonin regulates the polarized state of Kupffer cells to alleviate nonalcoholic fatty liver disease through ROS-NF-κB.
Zhu Y; Ruan S; Shen H; Guan Q; Zhai L; Yang Y
Int Immunopharmacol; 2021 Dec; 101(Pt B):108290. PubMed ID: 34717194
[TBL] [Abstract][Full Text] [Related]
3. Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop.
Kong M; Peng Y; Qiu L
Acta Biomater; 2023 Jul; 164():435-446. PubMed ID: 37040811
[TBL] [Abstract][Full Text] [Related]
4. Angelica Sinensis Polysaccharide-Based Nanoparticles for Liver-Targeted Delivery of Oridonin.
Sun H; Nai J; Deng B; Zheng Z; Chen X; Zhang C; Sheng H; Zhu L
Molecules; 2024 Feb; 29(3):. PubMed ID: 38338476
[TBL] [Abstract][Full Text] [Related]
5. In vivo studies on the oridonin-loaded nanostructured lipid carriers.
Zheng D; Dai W; Zhang D; Duan C; Jia L; Liu Y; Zhang Q
Drug Deliv; 2012 Aug; 19(6):286-91. PubMed ID: 22928767
[TBL] [Abstract][Full Text] [Related]
6. Studies on the oridonin-loaded poly(D,L-lactic acid) nanoparticles in vitro and in vivo.
Xing J; Zhang D; Tan T
Int J Biol Macromol; 2007 Jan; 40(2):153-8. PubMed ID: 16901536
[TBL] [Abstract][Full Text] [Related]
7. Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease.
Li X; Chen XX; Xu Y; Xu XB; Wu WF; Zhao Q; Hu JN
Biomacromolecules; 2022 Jan; 23(1):409-423. PubMed ID: 34964604
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function.
Wang X; Wang J; Ying C; Xing Y; Su X; Men K
BMC Pharmacol Toxicol; 2024 Jan; 25(1):7. PubMed ID: 38173037
[TBL] [Abstract][Full Text] [Related]
9. Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease.
Fan N; Zhao J; Zhao W; Zhang X; Song Q; Shen Y; Shum HC; Wang Y; Rong J
J Control Release; 2022 Jul; 347():44-54. PubMed ID: 35483638
[TBL] [Abstract][Full Text] [Related]
10. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis.
Huang R; Guo F; Li Y; Liang Y; Li G; Fu P; Ma L
Phytomedicine; 2021 Nov; 92():153739. PubMed ID: 34592488
[TBL] [Abstract][Full Text] [Related]
11. RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin.
Xu J; Zhao JH; Liu Y; Feng NP; Zhang YT
Int J Nanomedicine; 2012; 7():211-9. PubMed ID: 22275836
[TBL] [Abstract][Full Text] [Related]
12. Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPARα-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease.
Du K; Huang X; Peng A; Yang Q; Chen D; Zhang J; Qi R
Mol Pharm; 2023 Jan; 20(1):159-171. PubMed ID: 36342356
[TBL] [Abstract][Full Text] [Related]
13. The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease.
Teng W; Zhao L; Yang S; Zhang C; Liu M; Luo J; Jin J; Zhang M; Bao C; Li D; Xiong W; Li Y; Ren F
J Control Release; 2019 Aug; 307():139-149. PubMed ID: 31233775
[TBL] [Abstract][Full Text] [Related]
14. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.
Liang J; Liu Y; Liu J; Li Z; Fan Q; Jiang Z; Yan F; Wang Z; Huang P; Feng N
J Nanobiotechnology; 2018 Sep; 16(1):64. PubMed ID: 30176941
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin.
Li C; Zhang D; Guo H; Hao L; Zheng D; Liu G; Shen J; Tian X; Zhang Q
Int J Pharm; 2013 May; 448(1):79-86. PubMed ID: 23518367
[TBL] [Abstract][Full Text] [Related]
16. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.
Zheng D; Duan C; Zhang D; Jia L; Liu G; Liu Y; Wang F; Li C; Guo H; Zhang Q
Int J Pharm; 2012 Oct; 436(1-2):379-86. PubMed ID: 22732673
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.
Li R; Zhu W; Huang P; Ding C; Tang Y; Lian P; Huang X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):730-738. PubMed ID: 35837772
[TBL] [Abstract][Full Text] [Related]
18. The water extract of Sophorae tonkinensis Radix et Rhizoma alleviates non-alcoholic fatty liver disease and its mechanism.
Zhao Q; Wei M; Zhang S; Huang Z; Lu B; Ji L
Phytomedicine; 2020 Oct; 77():153270. PubMed ID: 32702591
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers.
Jia L; Shen J; Zhang D; Duan C; Liu G; Zheng D; Tian X; Liu Y; Zhang Q
Int J Biol Macromol; 2012 Apr; 50(3):523-9. PubMed ID: 22301003
[TBL] [Abstract][Full Text] [Related]
20. Targeted Delivery of Celastrol via Chondroitin Sulfate Derived Hybrid Micelles for Alleviating Symptoms in Nonalcoholic Fatty Liver Disease.
Pan Y; Zhang Y; Ouyang H; Gong T; Zhang Z; Cao X; Fu Y
ACS Appl Bio Mater; 2023 Nov; 6(11):4877-4893. PubMed ID: 37890075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
